---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Effects of other drugs"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Effects of other drugs. Topics: Extrinsic participant-specific parameters and exposure: prurigo nodularis; Prior biologics, immunosuppressives, and oral doxepin: exclusion criteria. 2 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Barzolvolimab

<a id="topic-2.1.2.9.1-1"></a>

### Clinical drug interaction studies

No evidence found.

<a id="topic-2.1.2.9.1-2"></a>

### Extrinsic participant-specific parameters and exposure: prurigo nodularis

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Exposure was not influenced by intrinsic and extrinsic participant-specific parameters, including sex, weight, or treatment-emergent antidrug antibody status”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.9.1-3"></a>

### Prior biologics, immunosuppressives, and oral doxepin: exclusion criteria

> “Key exclusion criteria were receipt of prior biologic therapy (e.g., omalizumab, dupilumab, and ligelizumab) within the past 3 months or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half‐lives; treatment with doxepin (oral) within 4 weeks prior to study treatment; and any other skin disease associated with chronic itching that might confound study evaluations and results.”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
